04:52 AM EDT, 08/04/2026 (MT Newswires) -- Genedrive's (GDR.L) rapid pharmacogenetic test for the prevention of antibiotic-induced hearing loss in newborns was rolled out at Erasmus MC University Medical Center in Rotterdam, the Netherlands, on Monday. The Genedrive MT-RNR1 ID Kit is in practice at over 20 neonatal intensive care units in the UK and abroad, the London-listed point-of-care pharmacogenetic testing company said Tuesday.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.